LIPOZOID Liposomal Docosahexaenoic acid
Pre-Clinically Tested for Cognitive Health
Powered by Advanced LIPOZOID Liposomal Technology for Superior Absorption & Efficacy
Liposomal Docosahexaenoic Acid (DHA) — Preclinically Studied for Cognitive Health
Algae-derived DHA powder is a plant-based source of Docosahexaenoic Acid (DHA), an essential omega-3 fatty acid obtained from marine microalgae. Using our proprietary Lipozoid® technology, DHA algae oil is converted into a liposomal powder format, enhancing its stability, bioavailability, and efficacy.
The neuroprotective potential of Liposomal DHA has been preclinically evaluated against scopolamine-induced cognitive deficits in male Wistar rats. The study assessed parameters including acetylcholinesterase activity, oxidative stress markers, ELISA-based biomarker assays, and behavioral performance tests, demonstrating its potential in supporting cognitive function and brain health.
Behavioural Tests: A series of behavioral tests were conducted to evaluate the neuroprotective and cognitive-enhancing effects of Liposomal DHA in a scopolamine-induced cognitive impairment model.
Open Field Test
No significant differences in locomotor activity were observed among the groups, suggesting that the treatments had no effect on general motor function.
Novel Object Recognition (NOR) Test
Scopolamine administration impaired recognition memory, as indicated by a decrease in the discrimination index. Treatment with liposomal DHA at 50 mg/kg markedly enhanced recognition memory, as reflected by a significant improvement in the discrimination index.
Y-Maze Test
Scopolamine reduced spontaneous alternation behavior, indicating a decline in spatial working memory. Administration of liposomal DHA significantly restored alternation behavior, demonstrating an improvement in cognitive performance.
Morris Water Maze Test: Scopolamine administration increased escape latency and decreased the time spent in the target quadrant, indicating deficits in spatial learning and memory. Treatment with liposomal DHA effectively counteracted these impairments, significantly reducing escape latency and increasing time spent in the target quadrant.
Acetyl Cholinesterase Activity: Scopolamine administration significantly increased acetylcholinesterase activity in the prefrontal cortex and hippocampus. However, treatment with liposomal DHA significantly reduced acetylcholinesterase activity, thereby increasing acetylcholine availability and enhancing cholinergic transmission.
Oxidative stress markers: Scopolamine administration typically results in significantly elevated levels of malondialdehyde (MDA) and nitric oxide, along with a marked reduction in glutathione (GSH) levels, indicating increased oxidative stress and compromised antioxidant defense in the prefrontal cortex and hippocampus. Treatment with liposomal DHA effectively restored GSH levels and significantly reduced MDA and nitric oxide concentrations, suggesting enhanced antioxidant defense mechanisms and a reduction in oxidative stress in these brain regions.
Applications
CAPSULES
TABLETS
GUMMIES
SOLID BEVERAGES
